# Vera Therapeutics, Inc. (VERA)

> Source: Nexqual · https://nexqual.com/VERA · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Vera Therapeutics, Inc. (VERA), nexqual.com/VERA" · informational, not investment advice.

**Price:** USD 30.94 (+3.17% on the day) · last close of Oct 28, 2026; US market after hours, not a live price. Prev close 29.99 · day 29.77–31.13 · 52w 23.05–56.05 · market cap $2.23B · NGM

## Key facts
- Analysts: Buy (mean 2.07 on a 1–5 scale) (15 analysts), mean target USD 74.2 (range 34–100).
- Total return with dividends: 1Y +5.4% vs S&P 500 +13.6%; 5Y +59.9% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -1.61, revenue estimate $3.7M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$34.4M | -$90.9M | -$102M | -$167M | -$315M | -$416M |
| Net income | -$32.6M | -$89.1M | -$96.0M | -$152M | -$300M | -$402M |
| EPS (diluted) | -$2.43 | -$3.35 | -$2.25 | -$2.75 | -$4.66 | — |
| Free cash flow | -$23.7M | -$67.7M | -$92.2M | -$136M | -$242M | -$339M |
| Cash + short-term investments | $79.7M | $115M | $161M | $641M | $715M | — |
| Total debt | $4.9M | $24.8M | $49.9M | $50.7M | $74.8M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 5.5x · FCF yield -15.20% · Earnings yield -18.03% · Net cash $424M · EV $1.81B

## Analysts
Consensus Buy (mean 2.07 on a 1–5 scale), 15 analysts; mean target USD 74.2 (low 34, high 100).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | Leerink Partners | Initiated | Market Perform | $34 |
| 2026-09-08 | JP Morgan | Target raised | Overweight | $76 → $83 |
| 2026-08-17 | Wedbush | Reiterated | Neutral | $34 |
| 2026-08-12 | HC Wainwright & Co. | Target lowered | Buy | $125 → $90 |
| 2026-08-11 | Wedbush | Target lowered | Neutral | $43 → $34 |
| 2026-07-08 | TD Cowen | Target raised | Buy | $73 → $78 |
| 2026-07-08 | Guggenheim | Target raised | Buy | $56 → $76 |
| 2026-07-08 | Wedbush | Target raised | Neutral | $35 → $43 |
| 2026-07-08 | HC Wainwright & Co. | Target raised | Buy | $110 → $125 |
| 2026-07-07 | B of A Securities | Target raised | Buy | $65 → $70 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +5.4% | +59.9% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +5.4% | +9.8% |
| Volatility (annualized) | 61.3% | 95.1% |
| Max drawdown | -52.0% (Dec 2025→Oct 2026) | -82.4% (Nov 2021→Jan 2023) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 91.97 -0.23% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · PRAX (Praxis Precision Medicines, Inc) USD 285.48 +6.69%

## More
Full page: https://nexqual.com/VERA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-1.61 | $-1.54 | −$0.06 | $3.7M | 9 |
| Next quarter (ends 2026-12-31) | $-1.54 | $-1.41 | −$0.13 | $17.4M | 9 |
| Current fiscal year (ends 2026-12-31) | $-6.25 | $-6.21 | −$0.05 | $24.8M | 10 |
| Next fiscal year (ends 2027-12-31) | $-4.25 | $-3.86 | −$0.39 | $233.8M | 10 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±15.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 23 | 74.2% | ±15.1% |
| 2026-12-18 | 51 | 66.0% | ±19.7% |
| 2027-01-15 | 79 | 53.9% | ±20.0% |
| 2027-03-19 | 142 | 71.1% | ±34.8% |
| 2027-06-17 | 232 | 69.2% | ±42.4% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.52 | −$1.59 | Beat +4.4% | — |
| — | Quarter ended Mar 31, 2026 | −$1.69 | −$1.37 | Miss −23.4% | — |
| — | Quarter ended Dec 31, 2025 | −$1.39 | −$1.27 | Miss −9.4% | — |
| — | Quarter ended Sep 30, 2025 | −$1.26 | −$1.13 | Miss −11.5% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).